The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Novo Nordisk, PayPal, and Dell Technologies are modestly priced growth stocks with a lot of potential to rise higher. Buying ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

Wall Street’s main indices finished in the green but with lackluster gains, with the Nasdaq rising 0.27 percent, the S&P 500 ...

WW International relists on Nasdaq, pivoting to menopause care with GLP-1 drugs and coaching. Click here to read an analysis ...

About one-third of Canadians are now obese — with more weight gain happening during the pandemic, according to a new study.

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.